INS and type 1 diabetes mellitus: A clinical study on cholecalciferol adjunct to insulin in 38 recent-onset T1D aged 7–30 years old (treatment:19 patients, placebo: 19 patients) had no adverse events and yielded transient preservation of stimulated C-peptide at 12 months (P = .01) with a reduced rate of degradation at 18 months (Gabbay et al, 2012).